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Abstract
Acute Kidney Injury (AKI) remains a vexing clinical problem resulting in unacceptably high 
patient mortality, development of chronic kidney disease and accelerated progression to end stage 
kidney disease. Although clinical risks factors for developing AKI have been identified, there is no 
reasonable surveillance technique to definitively and rapidly diagnose and determine the extent of 
severity of AKI in any patient. Since patient outcomes correlate with the extent of injury, and 
effective therapy likely requires early intervention, the ability to rapidly diagnose and stratify 
patients by their level of kidney injury is paramount for translational progress. Many groups are 
developing and characterizing optical measurement techniques utilizing novel minimally invasive 
or non-invasive techniques that can quantify kidney function, independent of serum or urinary 
measurements. Utilization of both one and two compartmental models, as well as continuous 
monitoring, are being developed. The purpose of this review is to document the need for GFR 
measurement in AKI patients and discuss the approaches being taken to deliver this overdue 
technique that is necessary to help propel nephrology to individualization of care and therapeutic 
success.
INTRODUCTION: The Clinical Problem
AKI remains an untreatable and deadly disease process affecting 5–10% of all hospitalized 
and 30–50%of ICU patients with a mortality rate often exceeding 50% in the ICU setting.1–3 
The rate of AKI in hospitalized patients has been increasing for over 30 years and yet the 
clinical approach has remained the same. Over this period there has been a marked increase 
in AKI, with the age adjusted rate increasing from 18 to 365 per 100,000 population.1,2 AKI 
is associated with markedly increased mortality rates in numerous clinical situations 
including sepsis, following administration of radiocontrast dye and cardiovascular 
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surgery.4–8 Hsu et. al. quantified the increased incidence of non-dialysis and dialysis 
requiring AKI among members of an integrated health care delivery system (ref 8). In-
hospital death rates were much higher in AKI discharges than in non AKI discharges. Using 
the data collected, it was also calculated that at least 22.4% of the end stage kidney disease 
(ESKD) cases in the United States come from Medicare beneficiaries with hospital acquired 
AKI. Numerous publications utilizing clinical scoring criteria to stratify patients into stages 
based on the maximum serum creatinine levels and urinary output showed outcomes 
including mortality, length of hospital stay (LOS), ICU length of stay, hospital costs, and the 
need for renal replacement therapy related to the highest stage reached in this stratification 
system.9,10 These data indicate the severity of kidney injury is an outcomes prognostic 
indicator for both near and long terms. Data also implicated AKI as an initiator of chronic 
kidney disease (CKD) and the progression to end stage kidney disease (ESKD).11 Therefore, 
AKI prevalence in hospitalized patients is increasing at an alarming rate, injury severity 
determines hospital outcomes, and AKI accelerates both the development of CKD and its 
progression to ESKD.
Given the lack of progress in AKI what will it take to turn the tide?
Of major importance is the advancement of therapeutic options to prevent or minimize the 
near term and/or long term consequences of AKI. Agents effective against many different 
plausible preclinical therapeutic targets have been developed and advanced into clinical 
trials.12 Unfortunately, clinical trials in AKI have been unsuccessful and what was once seen 
as an attractive and large unmet need by pharmaceutical and biotech companies is now being 
viewed with skepticism, and some companies have even abandoned the area. Why the failure 
to translate highly effective preclinical therapies into effective clinical trials? This has often 
been attributed to inappropriate preclinical models and in response new models are being 
developed to more closely mimic the population being studied. The multifocal nature of AKI 
and the lack of human tissue to interrogate and compare to animal models at structural and 
molecular levels, as is being done in glomerular diseases 13, are also barriers to success. In 
this line of reasoning, individualization of therapy is not presently possible and likely won’t 
be in the near term. However, we now have the ability to quantify GFR and I will argue this 
should serve as the first step in individualizing therapy and quantifying the response to 
therapy, as the most appropriate measure of therapeutic success.
QUANTIFYING GFR AS A MEASURE OF KIDNEY FUNCTION
Serum Creatinine and eGFR
GFR, which measures the amount of plasma filtered through glomeruli within a given period 
of time, is a physiologic process and as such a direct indicator of kidney function. It became 
the cornerstone of Nephrology beginning with Homer Smith and was actively measured in 
clinical studies in the past.14 Unfortunately, the technique used then, inulin clearance, and 
the adaptations that followed remain cumbersome, time consuming and are not practical for 
studies in AKI for many reasons. Therefore, physicians base diagnostic and therapeutic 
decisions in millions of patients daily using a surrogate marker of GFR, that being the 
patient’s serum creatinine concentration.15,16
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While it is well known that reductions in the GFR, secondary to either acute or chronic 
kidney injury, are accompanied by increases in blood serum creatinine, the insensitivity of 
this surrogate marker as a measure of GFR is not uniformly appreciated. Neither serum 
creatinine nor one of several derived equations to estimate GFR (eGFR), based primarily on 
the serum creatinine, can be used in AKI, nor can they be used reliably over the range of 
GFRs.17–19 One of the many reasons for this is illustrated in figure 1 where measured GFR 
vs serum creatinine (SCr) is shown. The graph is divided into insensitive, transition and 
sensitive regions based on the slope of the curve. In higher GFR regions of this curve it takes 
a very large change in GFR to result in even a small measureable change in SCr. To illustrate 
this point, consider what a change of 0.3 mg/dl of SCr means, calculated using standard 
eGFR formulas as is shown in figure 1b. In the insensitive region of the GFR-SCr curve, 
(SCr 1.0) a change of 0.3 represents a loss of over 30 ml/min of baseline GFR. In the 
sensitive portion of the curve (SCr 2.5 mg/dl) an increase of 0.3 SCr represents a loss of 5 
ml/min. If one adds in the ability of the kidney to further increase GFR with stimuli such as 
a protein load or stress, the so called “renal reserve” or “augmented renal clearance”, then 
one can see why SCr or eGFR cannot provide an adequate measure of GFR change in this 
portion of the curve.
Renal reserve (RR) is that portion of GFR above baseline that is activated by stress, a protein 
load, amino acid infusion or glucagon infusion. It is felt to be proportionally lost as baseline 
GFR decreases, but very little is known about RR in CKD and aging patients. The most 
recent study showed no predictable effect on RR in patients with variable levels of GFR.20 
Chronic activation of RR occurs in diabetic patients and may portend a higher risk for 
progression to CKD and ESRD. It has also been show by many investigators to be activated 
in critical care situations where GFRs have been documented with daily 24 hr creatinine 
clearances for many days in patients on the ventilator and those receiving vasopressors for 
hemodynamic support.21 There are no data regarding what happens in AKI, but it may well 
be that this portion of kidney function is activated and lost first prior to showing a loss in 
baseline GFR or a rise in SCr. In a patient with normal baseline GFR this means a change in 
SCr indicative of AKI would not occur until up to two thirds of the patient’s total GFR 
(baseline plus RR) was lost.
For example, take the transplant kidney donor studied prior to and post donation.22 In this 
study baseline and stimulated GFRs were measured pre-donation and compared to post 
donation baseline values. Following donation serum creatinine increased from 0.96 +/− 0.15 
to 1.29+/− 0.24 while baseline GFR decreased form 113 ml/min to 72 ml/min. The pre-
donation stimulated GFR was 143ml/min. Therefore, loss of one kidney, or 50% of total 
GFR, resulted in only an increase of 0.33 mg/dl in SCr, a loss of 41 ml/min of baseline GFR, 
but a loss of 71ml/min total GFR. This was exactly half of the total pre-donation stimulated 
or total GFR implying total engagement of the renal reserve post donation. At one year of 
follow up the SCr was unchanged. This also brings home the point that a 0.3mg/dl change in 
SCr in a patient with normal kidney function represents a major insult in overall kidney 
function. This may explain why AKI in patients with near normal GFRs have an increased 
hospital mortality compared to patients with CKD where a less severe injury results in an 
adequate SCr readout to document AKI.8 It may also explain why some patients with AKI 
according to urinary biomarkers, but without an elevation in SCr, have higher morbidity and 
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mortality than those with negative biomarkers and SCr.23 This so called “subclinical AKI” 
because of the insensitivity of SCr, is now well documented and represents a clear advantage 
of new urinary biomarkers over SCr. Clearly, an injury resulting in the loss of 25ml/min 
GFR in a patient with normal kidney function could have less than a 0.3 mg/dl change in 
SCr and yet have positive urinary biomarkers. This would be unlikely in a patient with CKD 
where the loss of a few ml/min can be detected by a rise in SCr (Figure 1b).
The discrepancy between what an increase of 0.3mg/dl SCr means at different starting SCr 
brings up another important point, especially when one considers that all therapeutic trials in 
AKI are done on patients with CKD in order to increase the likelihood of “AKI events” in 
the study population. What this means is that clinical trialists have shifted the study 
population to those giving a large change in SCr for a small change in GFR to enhance their 
ability to detect the signal. Thus, patients with a 5–7 ml/min or less loss of GFR are studied 
rather than patients starting with a more normal GFR that would have to have a far larger 
loss of GFR due to the insensitivity of SCr. This is compounded when one considers renal 
reserve activation during AKI. Given that one of the therapeutic end points for registration of 
the drug is a permanent loss of GFR at 90 days is this a wise approach? Can we trust SCr to 
deliver on this endpoint? The standard techniques presently used to quantify GFR have 
coefficients of variability greater than the 5–7 ml/min and with a change of SCr of only 0.3 
in patients with CKD one is looking to register a drug on saving 1–2 ml/min (25% of 5–7ml/
min). Thus, one needs to consider this factor when designing studies for drug registration. 
Also, one has to ask if the drug will work in CKD patients for two reasons. First, likely it 
was only profiled for effectiveness in normal animals in preclinical studies. Second, the 
underlying process may already be in a stage where no therapy will work given the 
endothelial and tubular epithelial changes that occur in the later stages of CKD.
Other factors limit the ability of SCr to be used in AKI. Since both muscle mass (creatinine 
comes from creatinine released from muscle) and GFR determine a patient’s serum 
creatinine level, using serum creatinine as an indicator of GFR is highly patient-specific. For 
instance, a serum creatinine of 1.0 mg/dl is indicative of normal GFR (100ml/min/1.73 m2) 
in a 70 Kg male with normal muscle mass. However, in a 50 Kg male with muscle wasting a 
serum creatinine of 1.0 mg/dl is seen often with a GFR of only 50 ml/min. Therefore, 
formulas derived from large population studies have been developed to factor in patient 
weight, age, sex and race. However, these formulas are often inaccurate and misleading24–29 
This inaccuracy was also documented for creatinine clearances.30,31 For AKI in particular, 
this may relate to the known reduced production of creatinine in sepsis, at least in preclinical 
models.32
Finally, even in situations where SCr is stable the estimating equations have major 
limitations. In a recent review it was stated that “In usual practice, an eGFR equation is 
defined as having sufficient accuracy when at least 75% of the estimates fall within +/− 30% 
of the measured GFR.33 This means an eGFR of 50 indicates the patient’s measured GFR 
would fall between 65 and 35ml/min 75% of the time, and one in four patients would fall 
outside of this range. The clinical importance of this was recently reviewed.33 eGFR 
formulas are also difficult to use in population groups outside of the study population used 
for their derivation.27,28
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Renal reserve and muscle mass are also important factors in following a patient’s recovery 
with regard to permanent loss of kidney function. In a recent article Prowle and co-authors 
followed 700 patients with a 66% incidence of AKI following an ICU admission of five or 
more days.34 In these patients SCr led to an inaccurate and over estimate of kidney function 
in all patients, those with and without AKI. Even in patients with KDIGO stage III AKI no 
permanent loss of kidney function could be demonstrated at follow up. This was likely the 
result of muscle wasting, decompensation and likely the engagement of renal reserve. 
However, this was not determined. Very concerning is the “apparent” return to baseline 
kidney function, based on SCr or eGFR, following various levels of AKI including stage 
three in patients starting with normal or near normal function prior to the AKI event. How 
can a therapeutic be successful in this population given these results?
In addition, neither SCr nor eGFRs can be used in the setting of evolving or recovering AKI 
because of the time it takes to reach equilibrium creatinine values which are required for an 
accurate conversion. For example, although patients with acute kidney injury may develop 
an abrupt GFR decline the magnitude of this decline is only apparent after several days of 
equilibration if determined using a rising serum creatinine. If a patient was to lose 95% of 
their GFR secondary to AKI, the GFR would decrease from 100 to 5 ml/min rapidly but the 
serum creatinine would only rise by 1–2 mg/dl/day. This slow rise in serum creatinine 
eliminates the ability to diagnose the injury rapidly and it is also not possible to determine 
the total extent of injury for days. To find a way around this two studies have used modeling 
to both redefine AKI (Waikar and Bonventre JASN 20: 672, 2009) and estimate a “kinetic 
GFR” when plasma creatinine is changing (Chen, S. JASN 24:877, 2013) However, the 
kinetic estimation of GFR required determination of the volume of distribution, creatinine 
production rate and quantitative difference between consecutive plasma creatinines over a 
given time when the plasma creatinine was changing. This does not seem practical in the 
clinical setting.
Since the extent of decline in GFR, or eventual plateau in serum creatinine, correlates with 
morbidity, mortality and the potential for recovery 9,10,35,36 accurately determining GFR in 
patients with AKI is of great clinical importance including rapid diagnosis, stratification, and 
timely treatment. The inability to do this has markedly limited the ability to conduct a 
successful therapeutic trial in AKI. It is widely held that beginning therapy after 12 – 24 
hours of AKI may limit the success rate of any potential therapeutic agent. Therefore, a 
search for a diagnostic biomarker of kidney injury is now considered by many experts to be 
the highest priority in the AKI field.16,37,38 However, the extent of injury, rate of recovery, 
response to therapy and the magnitude of recovery are not approachable utilizing presently 
available structural biomarkers and a combination of both structural and functional 
determinants of AKI will be synergistic.
Determining Glomerular Filtration Rate
The rapid and accurate clinical determination of GFR has been a clinical goal for over fifty 
years. The clinical utility for a measured GFR (mGFR) is listed in Table 1. Collection of a 
24 hour urine and invasive techniques exist to approximate a patient’s GFR, but these 
approaches are cumbersome, error prone, expensive, time consuming, and can expose the 
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patient to potential harm including radiation or radiocontrast media.15 There is also not a 
rapid and accurate technique to determine GFR reliably in patients with AKI when the 
serum creatinine is rising or falling. Since release of creatinine by muscles is not consistent 
throughout the day, and is affected by acute diseases, short term urine collections can be 
misleading.31 To measure GFR accurately the ideal GFR marker should be small, retained 
within the vasculature, not protein bound, and freely filtered across the glomerulus. It should 
not be secreted into the urine, reabsorbed from the urine, or metabolized within the kidney 
so that the measured GFR would be equal to the urinary clearance of the marker after its 
intravenous infusion. Inulin, a small fructose polymer that is neither secreted, reabsorbed, 
nor metabolized, and cleared only by glomerular filtration, is the reference standard GFR 
marker. However, it is not retained exclusively within the intravascular volume as it also 
distributes into the interstitial volume to occupy the total extracellular fluid volume (ECF). 
Therefore, the disappearance of inulin, and other small molecular weight compounds used to 
quantify GFR from the intravascular volume, is governed by both interstitial space 
distribution and kidney clearance. This results in early rapid vascular clearance, due to 
interstitial redistribution, and kidney removal of the compound. To remove the interstitial 
distribution component from the equation the terminal elimination phase k constant is used 
as it relates directly to kidney removal of the compound. At this time the vascular and 
interstitial concentration of the GFR reporter are identical. This is why the one compartment 
model requires several hours of recurrent blood draws for an accurate determination. Other 
non-radioactive markers (such as iothalamate, iohexol, and polyfructosan) and radioactive 
ones (such as 125I-iothalamate and 51Cr-EDTA) are used for such studies. Radioactive GFR 
markers, such as 39 Cr-EDTA and 99mTc-DTPA (99m-Technetium diethylene triamine 
pentaacetate) have been used in conjunction with a radiation detector to monitor GFR in 
patients with AKI at rates close to real-time.40,41 The measured plasma clearance showed 
excellent correlations with GFRs simultaneously measured using the standard method with 
urine collection.40,41 However, the use of radioactive GFR markers makes this method not 
attractive for obvious reasons, and Cr-EDTA cannot be used in the United States. By using a 
fluorescent GFR marker, such as FITC-inulin, with a bolus intravenous infusion followed 
with drawing blood samples at multiple time points, one can accurately determine a 
clearance rate constant and, if plasma volume is known, a measured GFR.42–45 Medical 
imaging with the development of a suitable contrast agent, for instance magnetic resonance 
imaging (MRI) techniques, will be useful for providing kidney functional diagnostics.46–49 
The downside of using such technologies is the low accessibility, associated high cost, 
difficulty repeating the study, and the need to transport the patient for the study.
In summary, the rapid and accurate measurement of GFR in AKI is important for diagnosis, 
severity of injury stratification, and potential therapeutic purposes. Rapid identification and 
determination of the extent of AKI will allow for early treatment, including dialysis 
initiation, as well as enrollment and stratification in clinical studies. It could also be used to 
determine the effect of a clinical maneuver on GFR such as volume resuscitation, and the 
loss of baseline and or total GFR subsequent to the injury event. Therefore, this would 
represent a technical advance of major clinical importance, especially in high risk patients.
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Translating Fluorescence Measurements into Clinical Observations Progress in the Area of 
Fluorescence Tissue Imaging
Since the beginning of 1990, the idea of using visible or near infrared (IR) light to image 
live tissue has been gradually developed in both theory and in practice. According to photon 
diffusion theories (also known as diffusive photon or photon migration) which consider the 
non-coherent property or the wave nature of photons50–53, one can detect photons injected 
into the tissue at a relatively large distance (up to 10 cm and beyond) away from the light 
source.52,54,55 Similarly, one can also detect fluorescence photons emitted from the tissue by 
delivering excitation light into the tissue at a distance away from the detectors.51,56–61 
Tissue properties can be studied and measured using photon diffusion technologies.39,62,63 
Intrinsically, optical techniques that use non-ionizing radiation are either minimally- or non-
invasive. They can empower the diagnosis of diseases with high sensitivity, speed and 
accuracy.
Two-photon fluorescence microscopy is a promising technique especially for imaging of 
highly scattering biological specimens.64–69 With this technique ultrafast near-infrared pulse 
lasers provide long wavelength low energy photons used as the excitation light source 
allowing for deeper tissue penetration than visible and ultraviolet light. The benefits of using 
two-photon excitation for viable tissue imaging have been studied and reviewed.70–72 This 
imaging technique holds particular promise for studying kidney functions as it allows direct 
observations of local regions of the kidney, such as the glomerulus, proximal tubule cells, 
and distal tubule cells, with subcellular and sub-micron resolution and at the same time with 
nanomolar to micromolar concentration sensitivity.67,73–77 In the past few years significant 
progress has been made in using two-photon excitation fluorescence microscopy to study 
kidney function and dysfunction by imaging live animals.65,67–69,75–82 In particular, 
quantitative fluorescent approaches have been developed for determining numerous kidney 
functions including GFR.65,67–69,75–85 Several groups of investigators are working on this 
same idea as is shown by recent publications (table 2).83,86–93
Initial studies in mice showed a single injection of FITC-inulin could be used to quantify 
GFR with normal, reduced and increased GFR.43 Continuous infusions of FITC-inulin have 
also been used with success in mice 94 to quantify hyperfiltration in diabetic mice. Sinistrin, 
a fluorescent derivative of inulin that has increased solubility, has also been used in bolus 
and continuous infusion studies in rats.90,91,95 These later studies were accomplished using a 
transcutaneous monitor of fluorescence reading the ECF fluorescence. Sinistrin has also 
been used in humans with variable levels of kidney function including patients with 
augmented renal clearance.96,97 Other dyes have also been studied in rodent models and 
lifetime-decomposition measurements of FITC-sinistrin have been used to quantify 
GFR.89,98 The use of lifetime analysis allowed a reduction in sinistrin dose by factor of 200. 
However, all of these studies had to use a single compartment model as the fluorescent 
signal comes for the ECF. This approach requires equilibration of the injected fluorescent 
marker with the ECF and increases the amount of marker needed for adequate signals. It also 
requires an estimate of the plasma volume (PV) as actual concentrations of the markers are 
not determined. Thus, a rate constant is determined for removal of the substance from the 
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plasma and the rate constant must be multiplied by an estimated PV. As multiple factors 
affect PV an estimate based on normal physiology may give misleading results.
Developing a Bedside Measured Two-Compartment mGFR Technique
Translation of fluorescent technology into quantitative in vivo clinical applications has been 
rare due to its complex and platform-dependent nature.99 As a result accurate determination 
of the concentration of fluorescent molecules under in vivo conditions is usually very 
difficult. Translation requires refining an approach initially developed in rats that would 
allow rapid direct quantification of vascular fluorescence for quantitative analysis of GFR 
and plasma volume.83 Three components are necessary to translate from the microscope to 
the bedside. These include a two component fluorescent injectate consisting of a high 
molecular weight PV indicator and a small molecular weight glomerular filtration indicator. 
To measure GFR accurately the ideal GFR plasma volume marker molecule should be 
retained within the vasculature, not be metabolized within the vascular compartment during 
the study, have a glomerular sieving coefficient (GSC) of 0.0, and it should not be secreted 
by the kidney. The ideal GFR filtration reporter molecule is freely filterable by the kidney 
(GSC of 1.0), does not bind to other plasma constituents, is not secreted by the kidney, and 
does not undergo metabolism during the procedure. Following a bolus infusion of GFR 
reporter molecules the plasma concentration of these molecules decreases as a function of 
time and is dependent upon both kidney clearance and redistribution within the vasculature 
and into the extra cellular fluid (ECF). The large fluorescent PV marker molecule serves to 
quantify the plasma volume of distribution based on principles of dilution. It should be large 
enough not to “leak” into the ECF, even in disease states, to give reliable readouts during the 
timeframe of the study.
Dextrans are inert and highly water soluble molecules that can be correctly sized and have 
been used clinically for many decades. They are also easy to label with fluorescent 
molecules with a high conjugation ratio. These characteristics allow for very low dose 
volumes and mass to be given. This allows for very small amounts of fluorescent dextrans to 
be used in studies and has important clinical safety and financial implications. In addition, 
the use of one fluorescent dextran as a PV marker, and a second freely filterable small highly 
fluorescent reporter molecule to quantify the rate of plasma clearance as an assay for GFR, 
can replace the necessity of concentration measurements of the filtration reporter with 
relative fluorescence intensity determinations. The relatively stable and impermeable nature 
of the large marker molecule allows for accessing the plasma volume directly thus 
minimizing potential errors due to variations in PV with disease states and inaccurate 
estimates of time zero concentrations. Use of a large PV indicator such as 150kDa dextran 
molecule avoids movement of the molecule into the extracellular space especially in disease 
states like sepsis thus allowing for a stable measurement over time. Purity, in terms of the 
size distribution or molecular weight of the dextran molecules, is critical. The distribution of 
molecular weight about the mean weight plays an important role in how accurately GFR can 
be determined. Even though dextrans are widely used in medical applications, these previous 
applications did not require the stringent size control needed for use with the present 
technique.
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The second component necessary for a rapid bedside determination is a two compartment 
model. Using a two compartment mathematical model one can reduce the time it takes to 
determine a GFR compared to a one compartment model. The GFR rate constant, and 
apparent volume of distribution (Vd) of the PV indicator molecule, can be measured by 
monitoring the plasma concentration of the fluorescently labeled GFR filtration molecule 
over time and dilution equilibrium value of the PV indicator molecule. The two 
compartments in question are the vascular and interstitial spaces. The basic assumption for 
this model is that after the bolus injection the infused filtration molecule, but not the larger 
PV indicator molecule, will distribute from the vascular space to interstitial space, but true 
plasma clearance by the kidney only occurs from the vascular space.
The plasma clearance rate and the inter-compartment clearance rate are denoted as G and α, 
respectively. The virtual volume for the vascular and interstitial spaces are V1 and V2, 
respectively. The two-compartment pharmacokinetics model, as described 
previously,44,83,100–102 has been extensively used for determination of GFR. The 
conventional single compartment approach to determine GFR requires determinations of the 
plasma concentrations of the filtration reporter from multiple blood samples drawn over 5–6 
hours as the early phase rapid decay makes it impossible to properly determine the T0 point 
using only the curve fit of later sample times. Thus, single compartment models rely on 
much longer test times to compensate for missing this early data. As was demonstrated 
recently,83,92 both requirements can be eliminated by using the two-compartment model. We 
applied this approach to studies in large animals using the optical fiber device.92 Following 
bolus injection the infused smaller dextran molecules were cleared by the kidneys and 
distributed from the vascular into the interstitial space, but did not move intracellularly; the 
large dextran molecules were retained in the vascular space during the course of the study. 
Based on the principle of dilution, a true vascular volume can be calculated from a 10 
minute blood draw. Using the measured vascular volume and known dose, a virtual T0 point 
can be accurately calculated. The concentration of the freely kidney filterable reporter (5 
kDa fluorescein-dextran) over time determined by the background-corrected fluorescence, 
including the derived T0 point, was fit to a bi-exponential equation (Eq.1) using the Sigma 
plot program to obtain the amplitudes and decay constants:
(1)
where Ct was the concentration in the plasma at time, t, A and B are the initial amplitudes, 
and α and β are the decay rates. GFR, G, was then calculated using the equation:
(2)
Since its introduction,102 the two-compartment model has been applied in a number of renal 
studies on animal subjects 43,45,101 as well as on human subjects.100,103,104 It has been 
shown in these studies to be an effective approach in plasma clearance analysis and GFR 
determination.
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When the inter-compartment volume exchange rate approaches 0, this model collapses to a 
single compartment model. Thomaseth and Amici 105 used this simplified model to measure 
plasma clearance of 125 I iothalamate for GFR and Vd assessment on patients under 
peritoneal dialysis (PD).
The third and final component is a fluorescent detector including software for reading, 
analyzing, and reporting data, a user interface to control the apparatus and view results, and 
the ability to send and receive fluorescent signals. Plasma samples, from timed blood draws, 
are placed into the instrument and analyzed for the fluorescence intensity. The fluorescence 
characteristics of the molecules make them easy to read compared to other types of GFR 
markers. The main difference between single channel designs and the two channel design is 
an additional dichroic filter within holders, separated from the main block by spacers used to 
combine light from the 490 nm LED and 595 nm LED together. This set-up allows for both 
molecules to be read simultaneously on each sample, decreasing overall sample processing 
time and instrument size.
A rapid determination of GFR has multiple advantages. First, it can be used for bedside 
determinations in the hospital where rapid, 10 minutes for PV and less than 120 minutes for 
GFR, are necessary for clinical decisions. This approach also allows for a shortened time for 
outpatient determinations. Finally, it allows for measurement of renal reserve and therefore 
total GFR. To accomplish this either an IV infusion of an amino acid mixture or a protein 
meal can be used.106,107 Using a two compartment model this can be done either following a 
baseline measurement of GFR by repeating the study post stimulation or without a baseline 
measurement by a GFR study one hour post stimulation. The former allows for 
determination of both baseline GFR, and total GFR with the difference being renal reserve. 
Not known is whether measuring the total GFR will allow for more sensitive and accurate 
measurements of kidney function and its loss during disease. Measuring renal reserve would 
also likely give early insight into hyperfiltration in diabetics allowing for earlier initiation of 
therapies to reduce intraglomerular pressure.
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Figure 1. 
Figure 1A. Serum creatinine vs inulin measured GFR adopted from Botev R et al.24
Figure 1B. Baseline serum creatinine of an idealized 70kg, 40 year old male vs the change in 
GFR that it would take to result in a 0.3mg/dl change in serum creatinine (the definition of 
AKI), using the CKD-EPI formula.
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Figure 2. 
Idealized GFR vs serum creatinine showing renal reserve in a patient with normal kidney 
function.
Molitoris and Reilly Page 18
Semin Nephrol. Author manuscript; available in PMC 2017 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Molitoris and Reilly Page 19
Table 1
Clinical Applications for Real-Time GFR
• Screen test for hospital-acquired kidney injury in patients with or without preexisting kidney damage
– Diagnosis
– Quantifying severity of injury
– Asses therapeutic response
• Drug-dosage adjustments in patients with acute or chronic kidney dysfunction
• Risk assessment of AKI
• Rate of progression of kidney disease, quantify baseline, and renal reserve
• Monitor patients requiring repeated administration of nephrotoxic drugs
• Indirect assessment of visceral organ perfusion, such as during prolonged anesthesia
• Clinical trials for determining actual loss of total kidney function over a period of time
• Screening for hyperfiltration in diabetics to identify an early signal of pending CKD development
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